BIG PHARMA BUYS AND BURIES INNOVATIVE COMPANIES USING ANTICOMPETITIVE MERGERS

BIG PHARMA BUYS AND BURIES INNOVATIVE COMPANIES USING ANTICOMPETITIVE MERGERS

U.S. antitrust policy should be strengthened to address anticompetitive mergers in the pharmaceutical sector, particularly “killer acquisitions” that eliminate emerging competition. This includes lowering reporting thresholds in highly concentrated health care markets, requiring the inclusion of intangible assets such as patents in merger evaluations, and applying heightened scrutiny to transactions involving overlapping products. Regulators, including the Federal Trade Commission and the Department of Justice, should also require enforceable commitments to continued product development and post-merger transparency. These reforms would help preserve competition, promote innovation, and protect patients from high prices and reduced access to essential therapies.

BIG PHARMA PARTNERING WITH TELEHEALTH — HELPING PATIENTS or ENCOURAGING BAD PRESCRIBING ?

BIG PHARMA PARTNERING WITH TELEHEALTH — HELPING PATIENTS or ENCOURAGING BAD PRESCRIBING ?

Current rules from the FDA apply to drug companies’ ads, requiring them to show risks. But telehealth companies aren’t held to the same standards — even when they promote the same drugs. That could mislead patients.
Are doctors favoring drugs from partner companies?
Are patients being properly evaluated?
What exactly are the companies paying each other for?
Is the Anti-Kickback Statute (AKS) being violated?